Inhibition of protein kinase C-beta by ruboxistaurin preserves cardiac function and reduces extracellular matrix production in diabetic cardiomyopathy - PubMed (original) (raw)
Inhibition of protein kinase C-beta by ruboxistaurin preserves cardiac function and reduces extracellular matrix production in diabetic cardiomyopathy
Kim A Connelly et al. Circ Heart Fail. 2009 Mar.
Abstract
Background: Heart failure is a common cause of morbidity and mortality in diabetic patients that frequently manifests in the absence of impaired left ventricular systolic function. In contrast to the strong evidence base for the treatment of systolic heart failure, the treatment of heart failure with preserved left ventricular function is uncertain, and therapeutic targets beyond blockade of the renin-angiotensin-aldosterone and beta-adrenergic systems are being sought. One such target is the beta-isoform of protein kinase C (PKC), implicated in both the complications of diabetes and in cardiac dysfunction in the nondiabetic setting.
Methods and results: Using a hemodynamically validated rodent model of diabetic diastolic heart failure, the (mRen-2)27 transgenic rat, we sought to determine whether selective inhibition of PKC-beta would preserve cardiac function and reduce structural injury. Diabetic rats were randomized to receive either vehicle or the PKC-beta inhibitor, ruboxistaurin (20 mg/kg per d) and followed for 6 weeks. Compared with untreated animals, ruboxistaurin-treated diabetic rats demonstrated preserved systolic and diastolic function, as measured by the slope of preload recruitable stroke work relationship (P<0.05) and the slope of the end-diastolic pressure volume relationship (P<0.01). Collagen I deposition and cardiomyocyte hypertrophy were both reduced in diabetic animals treated with ruboxistaurin (P<0.01), as was phosphorylated-Smad2, an index of transforming growth factor-beta activity (P<0.01 for all, versus untreated diabetic rats).
Conclusions: PKC-ss inhibition attenuated diastolic dysfunction, myocyte hypertrophy, and collagen deposition and preserved cardiac contractility. PKC-beta inhibition may represent a novel therapeutic strategy for the prevention of diabetes-associated cardiac dysfunction.
Similar articles
- PKCβ inhibition with ruboxistaurin reduces oxidative stress and attenuates left ventricular hypertrophy and dysfunction in rats with streptozotocin-induced diabetes.
Liu Y, Lei S, Gao X, Mao X, Wang T, Wong GT, Vanhoutte PM, Irwin MG, Xia Z. Liu Y, et al. Clin Sci (Lond). 2012 Feb;122(4):161-73. doi: 10.1042/CS20110176. Clin Sci (Lond). 2012. PMID: 21892921 - Protein kinase C{alpha}, but not PKC{beta} or PKC{gamma}, regulates contractility and heart failure susceptibility: implications for ruboxistaurin as a novel therapeutic approach.
Liu Q, Chen X, Macdonnell SM, Kranias EG, Lorenz JN, Leitges M, Houser SR, Molkentin JD. Liu Q, et al. Circ Res. 2009 Jul 17;105(2):194-200. doi: 10.1161/CIRCRESAHA.109.195313. Epub 2009 Jun 25. Circ Res. 2009. PMID: 19556521 Free PMC article. - Functional, structural and molecular aspects of diastolic heart failure in the diabetic (mRen-2)27 rat.
Connelly KA, Kelly DJ, Zhang Y, Prior DL, Martin J, Cox AJ, Thai K, Feneley MP, Tsoporis J, White KE, Krum H, Gilbert RE. Connelly KA, et al. Cardiovasc Res. 2007 Nov 1;76(2):280-91. doi: 10.1016/j.cardiores.2007.06.022. Epub 2007 Jun 29. Cardiovasc Res. 2007. PMID: 17716638 - A novel potential therapy for diabetic nephropathy and vascular complications: protein kinase C beta inhibition.
Tuttle KR, Anderson PW. Tuttle KR, et al. Am J Kidney Dis. 2003 Sep;42(3):456-65. doi: 10.1016/s0272-6386(03)00741-8. Am J Kidney Dis. 2003. PMID: 12955673 Review. - Ruboxistaurin mesilate hydrate for diabetic retinopathy.
Schwartz SG, Flynn HW Jr, Aiello LP. Schwartz SG, et al. Drugs Today (Barc). 2009 Apr;45(4):269-74. doi: 10.1358/dot.2009.45.4.1354195. Drugs Today (Barc). 2009. PMID: 19499092 Review.
Cited by
- The potential roles of exosomes in pathological cardiomyocyte hypertrophy mechanisms and therapy: A review.
Zhang L, Xie F, Zhang F, Lu B. Zhang L, et al. Medicine (Baltimore). 2024 Apr 26;103(17):e37994. doi: 10.1097/MD.0000000000037994. Medicine (Baltimore). 2024. PMID: 38669371 Free PMC article. Review. - Lipidomics Reveals Myocardial Lipid Composition in a Murine Model of Insulin Resistance Induced by a High-Fat Diet.
Girona J, Soler O, Samino S, Junza A, Martínez-Micaelo N, García-Altares M, Ràfols P, Esteban Y, Yanes O, Correig X, Masana L, Rodríguez-Calvo R. Girona J, et al. Int J Mol Sci. 2024 Feb 26;25(5):2702. doi: 10.3390/ijms25052702. Int J Mol Sci. 2024. PMID: 38473949 Free PMC article. - An Update on Protein Kinases as Therapeutic Targets-Part I: Protein Kinase C Activation and Its Role in Cancer and Cardiovascular Diseases.
Silnitsky S, Rubin SJS, Zerihun M, Qvit N. Silnitsky S, et al. Int J Mol Sci. 2023 Dec 18;24(24):17600. doi: 10.3390/ijms242417600. Int J Mol Sci. 2023. PMID: 38139428 Free PMC article. Review. - A protein kinase C α and β inhibitor blunts hyperphagia to halt renal function decline and reduces adiposity in a rat model of obesity-driven type 2 diabetes.
Wang J, Casimiro-Garcia A, Johnson BG, Duffen J, Cain M, Savary L, Wang S, Nambiar P, Lech M, Zhao S, Xi L, Zhan Y, Olson J, Stejskal JA, Lin H, Zhang B, Martinez RV, Masek-Hammerman K, Schlerman FJ, Dower K. Wang J, et al. Sci Rep. 2023 Oct 7;13(1):16919. doi: 10.1038/s41598-023-43759-7. Sci Rep. 2023. PMID: 37805649 Free PMC article. - Emerging Roles of Phospholipase C Beta Isozymes as Potential Biomarkers in Cardiac Disorders.
Fazio A, Evangelisti C, Cappellini A, Mongiorgi S, Koufi FD, Neri I, Marvi MV, Russo M, Ghigo A, Manzoli L, Fiume R, Ratti S. Fazio A, et al. Int J Mol Sci. 2023 Aug 23;24(17):13096. doi: 10.3390/ijms241713096. Int J Mol Sci. 2023. PMID: 37685903 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical